An investigation on behalf of investors in Transenterix Inc(NYSEMKT:TRXC) shares over potential wrongdoing at Transenterix Incwas announced and NYSEMKT:TRXC stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/01/2016 --An investigation on behalf of current long-term investors in shares of Transenterix Inc (NYSEMKT:TRXC) was announced over potential breaches of fiduciary duties by certain directors at Transenterix.

Investors who purchased shares of Transenterix Inc (NYSEMKT:TRXC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Transenterix directors breached their fiduciary duties and caused damage to the company and its shareholders.

On April 20, 2016, Transenterix Inc announced that the Food and Drug Administration ("FDA") notified Transenterix Inc on April 19, 2016 of its determination that the "SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission."

Shares of Transenterix Inc NYSEMKT:TRXC declined to a slow as $1.28 per share on April 21, 2016.

Those who purchased shares of Transenterix Inchave certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com